Finding the big picture for Alzheimer’sThe $4m Oskar Fischer Prize hopes to catalyse a breakthrough in Alzheimer’s research by encouraging a ‘big picture’ Share XFinding the big picture for Alzheimer’shttps://pharmaphorum.com/r-d/views-analysis-r-d/finding-the-big-picture-for-alzheimers/
Alzheimer’s blood test could boost research after successive trial failuresA blood test could be used to diagnose Alzheimer’s before symptoms arise, providing an alternative to expensive brain Share XAlzheimer’s blood test could boost research after successive trial failureshttps://pharmaphorum.com/news/alzheimers-blood-test-could-boost-research-after-successive-trial-failures/
Neurametrix aims to expand Alzheimer’s typing test in Pacific regionUS medical device firm Neurametrix has struck an agreement with N-Strategy Consulting Services (NSCS) to invest in a Share XNeurametrix aims to expand Alzheimer’s typing test in Pacific regionhttps://pharmaphorum.com/news/neurametrix-aims-to-expand-alzheimers-typing-test-in-pacific-region/
Novartis and Amgen axe BACE drug for Alzheimer’sAnother Alzheimer’s disease drug has been axed after Novartis, Amgen and the Banner Alzheimer’s Institute decided to end Share XNovartis and Amgen axe BACE drug for Alzheimer’shttps://pharmaphorum.com/news/novartis-and-amgen-axe-bace-drug-for-alzheimers/
Scientists recreate blood-brain barrier on a chipScientists in Israel and the US have duplicated the blood-brain barrier in a chip using human stem cells, Share XScientists recreate blood-brain barrier on a chiphttps://pharmaphorum.com/news/scientists-recreate-blood-brain-barrier-on-a-chip/
A bright future for CNS and Alzheimer’s?Swiss biotech Asceneuron is developing what could be the first treatment for progressive supranuclear palsy (PSP), a rare Share XA bright future for CNS and Alzheimer’s?https://pharmaphorum.com/r-d/views-analysis-r-d/a-bright-future-for-cns-and-alzheimers/
Biogen’s R&D strategy fails to impress after Alzheimer’s trial flopThe dust has settled at Biogen following the company’s disastrous announcement that it was ending development of Alzheimer’s Share XBiogen’s R&D strategy fails to impress after Alzheimer’s trial flophttps://pharmaphorum.com/news/biogens-rd-strategy-fails-to-impress-after-alzheimers-trial-flop/
Biogen, Eisai hit hard as Alzheimer’s drug is abandonedThe dwindling number of amyloid-targeting drugs in development for Alzheimer’s disease (AD) has been reduced by one more, Share XBiogen, Eisai hit hard as Alzheimer’s drug is abandonedhttps://pharmaphorum.com/news/biogen-eisai-hit-hard-as-alzheimers-drug-is-abandoned/
AbbVie upscales Voyager alliance with new target, more cashAbbVie has extended its collaboration with gene therapy specialist Voyager Therapeutics, adding a new programme in Parkinson’s disease Share XAbbVie upscales Voyager alliance with new target, more cashhttps://pharmaphorum.com/news/abbvie-upscales-voyager-alliance-with-new-target-more-cash/
